David is a Principal Scientist on the Discovery Research Team at GentiBio. He joins GentiBio from Philadelphia-based biotech Integral Molecular, where he held several positions supporting both internal and external programs, including Molecular Biology Project Leader.
While at Integral, he oversaw the technology enabling their high-throughput site-directed mutagenesis platform. He contributed to optimization and implementation of processes enabling antibody discovery against integral membrane proteins via phage panning against virus-like particles. He subsequently led the development of in-house phage library construction capabilities from immunized chickens, which enabled the isolation of the first antibodies to the exofacial face of the insulin-stimulated glucose transporter, GLUT4.
David is originally from Melbourne, Australia. He earned both his BSc (Hons) and PhD from The University of Melbourne. He departed the Southern Hemisphere to join the laboratory of Morris J. Birnbaum at The University of Pennsylvania as an HHMI Postdoctoral Fellow. There he studied the role of Akt isoform specificity in the regulation of insulin-stimulated GLUT4 translocation, glucose transport and lipolysis in adipocytes.
Outside the lab, David enjoys spending time with his wife and two cats, cycling and listening to music. He likes his coffee black and cold.